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In Brief
Peptide biomarker candidates
for the respiratory tract patho-
gens Streptococcus pneu-
moniae, Haemophilus influenzae,
Moraxella catarrhalis and Staph-
ylococcus aureus are presented.
First, bacterial cultures repre-
senting the genetic variability in
each of the four species, were
analyzed. The peptide biomarker
candidates were then experi-
mentally verified to be present in
a clinical situation by analyzing
true positive clinical samples.
The most promising peptide bio-
markers were used in a targeted
MS mode, demonstrating their
use for future clinical
implementation.
Graphical Abstract
Highlights
• Discovery of peptide biomarker candidates of respiratory tract pathogens S. pneumoniae, H. influ-
enzae, M. catarrhalis and S. aureus as target pathogens.
• Peptide biomarker candidates were experimentally verified in clinical samples.
• Targeted MS using promising peptide biomarker candidates shown as proof-of-concept.
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Discovery of Species-unique Peptide
Biomarkers of Bacterial Pathogens by Tandem
Mass Spectrometry-based Proteotyping*□S
Roger Karlsson‡§‡‡¶¶¶§§§, Annika Thorsell**¶¶¶, Margarita Gomila§§,
Francisco Salva`-Serra‡§¶§§, Hedvig E. Jakobsson§, Lucia Gonzales-Siles‡§,
Daniel Jae´n-Luchoro‡§, Susann Skovbjerg‡§, Johannes Fuchs**, Anders Karlsson‡‡,
Fredrik Boulund¶¶, Anna Johnning‡‡‡, Erik Kristiansson, and Edward R. B. Moore‡§¶
Mass spectrometry (MS) and proteomics offer compre-
hensive characterization and identification of microor-
ganisms and discovery of protein biomarkers that are
applicable for diagnostics of infectious diseases. The use
of biomarkers for diagnostics is widely applied in the
clinic and the use of peptide biomarkers is increasingly
being investigated for applications in the clinical labora-
tory. Respiratory-tract infections are a predominant
cause for medical treatment, although, clinical assess-
ments and standard clinical laboratory protocols are time-
consuming and often inadequate for reliable diagnoses.
Novel methods, preferably applied directly to clinical sam-
ples, excluding cultivation steps, are needed to improve
diagnostics of infectious diseases, provide adequate
treatment and reduce the use of antibiotics and associ-
ated development of antibiotic resistance. This study ap-
plied nano-liquid chromatography (LC) coupled with tan-
dem MS, with a bioinformatics pipeline and an in-house
database of curated high-quality reference genome se-
quences to identify species-unique peptides as potential
biomarkers for four bacterial pathogens commonly found
in respiratory tract infections (RTIs): Staphylococcus au-
reus; Moraxella catarrhalis; Haemophilus influenzae and
Streptococcus pneumoniae. The species-unique peptides
were initially identified in pure cultures of bacterial refer-
ence strains, reflecting the genomic variation in the four
species and, furthermore, in clinical respiratory tract sam-
ples, without prior cultivation, elucidating proteins ex-
pressed in clinical conditions of infection. For each of the
four bacterial pathogens, the peptide biomarker candi-
dates most predominantly found in clinical samples, are
presented. Data are available via ProteomeXchange with
identifier PXD014522. As proof-of-principle, the most
promising species-unique peptides were applied in tar-
geted tandem MS-analyses of clinical samples and their
relevance for identifications of the pathogens, i.e. proteo-
typing, was validated, thus demonstrating their potential
as peptide biomarker candidates for diagnostics of infec-
tious diseases. Molecular & Cellular Proteomics 19:
518–528, 2020. DOI: 10.1074/mcp.RA119.001667.
Respiratory tract infections (RTIs)1 are a major reason for
hospital admissions and are often treated with antibiotics (1).
Today, a clinical assessment performed by the physician, is
mainly based on symptoms, together with supporting clinical
laboratory microbiological confirmation (2). Microbiological
characterization of a clinical sample traditionally relies on
cultivation of bacteria, which not only takes precious time, but
in many cases is inconclusive because of the difficulty to
recover viable bacteria. For example, in only 50% of the
cases, are Streptococcus pneumoniae, a responsible agent
for pneumococcal infections, recovered by culturing (3). Be-
cause bacterial infection can lead rapidly to invasive life-
threatening situations, physicians may prescribe broad-spec-
trum antibiotics before knowing whether the infection is
caused by bacteria or virus. Overuse of broad-spectrum an-
tibiotics is a significant contributor to the emergence of anti-
microbial resistance (AMR). One of the key counter-measures
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in the battle against AMR will be the development of im-
proved, rapid, accurate and comprehensive diagnostic
methods.
DNA-based diagnostic approaches, such as real-time po-
lymerase chain reaction (RT-PCR) is currently implemented in
the routine protocols of the clinical microbiology laboratory
and whole-genome sequencing is increasingly applied. How-
ever, PCR is a targeted approach and, thus, detects and
identifies only the known and selected targets, which can lead
to biased results and insufficient species resolution and char-
acterization. One example is in the differentiation of closely
related species within the Mitis Group of the genus Strepto-
coccus, using PCR-based analyses of house-keeping genes
or virulence factors (4–6).
Matrix-Assisted Laser Desorption/Ionization-Time-Of-Flight
(MALDI-TOF) MS-based microbial species identification has
emerged as an alternative to traditional phenotypic- or geno-
typic-based methods (7–10). Demonstrating benefits, such as
reliable species-level resolution, in most cases, ease-of-use
and speed of processing samples, as well as low cost per
analysis, MALDI-TOF MS identification is now used in clinics
world-wide. However, a significant drawback of MALDI-TOF
MS analyses is that it, in most cases, requires time-consum-
ing cultivation and isolation of the relevant microorganisms.
Further drawbacks include limitations in discriminating closely
related species, including some species of the Mitis Group of
the genus Streptococcus, and, except in some limited cases
(11–13), it has proven ineffective for obtaining information on
characteristic features, such as AMR and virulence (14).
To increase the discriminative power and resolution for
differentiating closely related species, even to strain-level typ-
ing, tandem MS approaches at the peptide level have been
employed (14–21). Peptide biomarker discovery has been
facilitated by development of MS-instruments performing bot-
tom-up “high-resolution accurate-mass (HRAM)” tandem MS
proteomics, enabling identification of thousands of peptides
simultaneously, in a single analysis (16). At the peptide level,
tandem MS has the power to elucidate expressed point mu-
tations (22), enabling high levels of resolution. Biomarkers for
resistance and virulence factors can be detected simultane-
ously in the same analysis, providing crucial information for
diagnoses and proper treatments (23, 24).
Previously, we have shown that peptide biomarkers have
the power to differentiate bacterial species (14), as well as
strains within the same species (18). This “proteotyping” ap-
proach (14, 25, 26) can also be used for differentiating taxo-
nomically-close species, such as the pathogen S. pneu-
moniae from commensal species, S. pseudopneumoniae and
S. mitis of the Mitis Group of the genus Streptococcus (14). In
the present study, the workflow combines HRAM tandem MS
and the TCUP (Typing and Characterization of bacteria Using
bottom-up tandem mass spectrometry Proteomics) bioinfor-
matics pipeline (27) in the search for novel species-unique
peptides as potential biomarkers for the respiratory tract
pathogens, Staphylococcus aureus, Moraxella catarrhalis,
Haemophilus influenzae and Streptococcus pneumoniae. In
contrast to traditional cultivation-based methodologies, pro-
teotyping is not relying on recovery of cultivable cells, but can
be applied directly to clinical samples. The purpose of this
study was to initially identify species-unique peptides as po-
tential peptide biomarker candidates from bacterial cultures
of reference strains of the target bacterial species and then to
confirm these biomarker candidates in clinical respiratory-
tract samples without any cultivation step (Fig. 1).
EXPERIMENTAL PROCEDURES
Cultivation and Classification of Bacteria—Bacterial strains were
selected of each of four common respiratory-tract infectious bacterial
species: S. aureus (12 strains), M. catarrhalis (11 strains), H. influenzae
(9 strains), and S. pneumoniae (7 strains); obtained from the Culture
Collection, University of Gothenburg, Gothenburg, Sweden (CCUG;
www.ccug.se) (supplemental Table S1). Cultures were grown over-
night in the following way: S. aureus was grown on Blood Agar, at
37 °C, aerobically; M. catarrhalis and S. pneumoniae were grown on
Blood Agar, at 37 °C, with 5% CO2; H. influenzae strains were grown
on Chocolate Agar medium, at 36 °C, with 5% CO2. The classifica-
tions of the selected strains of H. influenzae, M. catarrhalis were
confirmed by 16S rRNA gene sequence determinations and compar-
ative sequence analyses (28). Classifications of the selected strains of
S. aureus were confirmed by 16S rRNA gene and sodA sequence
analyses (29). Classifications of the selected strains of S. pneumoniae
were confirmed by whole genome sequence Average Nucleotide
Identity based on BLAST (ANIb) analyses (30), using JSpeciesWS
(31), against the genome sequence of S. pneumoniae NCTC 7465T
(GenBank accession number: LN831051).
Peptide Generation from Bacterial Cultures—Bacterial biomass
was collected from fresh cultures and suspended in phosphate-
buffered saline (PBS). The bacteria were washed with PBS and lysed,
by bead beating (14). The bacterial lysates were frozen until further
analysis. The Lipid-based Protein Immobilization (LPI®) methodology
was employed for generating peptides from the cultured bacteria, as
described previously (14, 18, 27). Each strain of the four bacteria, S.
aureus, M. catarrhalis, H. influenzae, and S. pneumoniae, were di-
gested in triplicates (supplemental Fig. S1).
To digest bacterial proteins into peptides, the cell lysate was in-
jected into a LPI Hexalane FlowCell (Nanoxis Consulting AB, Gothen-
burg, Sweden, www.nanoxisconsulting.com; Patent Application No.
WO2006068619), using a pipette to fill the FlowCell channel (channel
volume of30 l). Proteins were immobilized to the FlowCell surface,
after incubation for 1 h, at room temperature. The FlowCell channels
were washed with 400 l of ammonium bicarbonate, using a syringe
pump, with a flow rate of 100 l/min. Enzymatic digestion of the
proteins was performed by injecting trypsin (V5111, Promega, Mad-
ison, WI) (2 g/ml in 20 mM ammonium bicarbonate, pH 8.0) into the
FlowCell channels and incubating for 1 h at room temperature. The
generated peptides were eluted by injecting 200 l ammonium bicar-
bonate buffer (20 mM, pH 8.0) into the channels. The eluted peptides
1 The abbreviations used are: RTI, respiratory tract infection; AMR,
antimicrobial resistance; TCUP, typing and characterization of bac-
teria using bottom-up tandem MS proteomics; HRAM, high-resolu-
tion accurate-mass; LPI, lipid-based protein immobilization; ANI, av-
erage nucleotide identity; BLAST, Basic Local Alignment Search Tool;
SDC, sodium deoxycholate; NCBI, National Center for Biotechnology
Information; PRM, parallel reaction monitoring; SRM, selected reac-
tion monitoring; MRM, multiple reaction monitoring.
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were collected at the outlet ports, using a pipette, and transferred into
tubes (2.0 ml, Axygen, Corning Life Sciences, MA). The peptide
solutions were incubated at room temperature overnight and subse-
quently frozen at 20 °C until analysis by MS. The peptide samples
were not reduced or alkylated prior to MS analysis.
Clinical Samples—Clinical respiratory tract samples (nasopharyn-
geal and nasal swabs, n  218), analyzed and reported as positive by
the Clinical Microbiology Laboratory (Sahlgrenska University Hospital,
Gothenburg, Sweden), were collected in Amies media (eSwab, Copan
Diagnostics, Inc, CA). The clinical samples were reported to contain at
least one of the four pathogens included in the study (S. aureus, M.
catarrhalis, H. influenzae and/or S. pneumoniae). In many cases, the
samples displayed co-infection with two or more of these pathogens.
The pathogens in clinical samples were confirmed by the standard,
accredited clinical microbiology laboratory protocols for selective and
differential isolation of bacteria, including subsequent identification by
MALDI-TOF MS analysis. Samples were supplemented with STGG
(Skim milk, Tryptone, Glucose, Glycerol) to bolster the viability of
bacteria as well as recovery of bacterial proteins during storage of
respiratory tract samples and frozen until processing (32). Only sam-
ples that were collected as part of the standard diagnostic protocols
were included in this study; no additional or extra sampling from
patients was carried out and no patient identifiable information was
collected; hence, informed consent was not required.
In the qualification phase, clinical respiratory tract samples, re-
ported to be negative for bacteria by cultivation-based protocols and
MALDI-TOF-MS, were spiked with cells of the type strains of the four
species H. influenzae (CCUG 23945T), M. catarrhalis (CCUG 353T), S.
aureus (CCUG 41582T) and S. pneumoniae (CCUG 28588T), to select
the most promising peptide biomarker candidates for the validation
phase. The number of added cells to the negative clinical samples
ranged from 100 cells/ml to 1 million cells/ml (supplemental Fig. S2).
Peptide Generation from Clinical Samples—The MolYsis kit (MolY-
sis Basic5 kit, Molzym GmbH & Co. Bremen, Germany) was used for
removal of human biomass, according to the supplier’s protocol, with
minor modifications. After sample treatment, the resulting bacterial
pellets were re-suspended in 120 l ammonium bicarbonate (20 mM
pH 8) and bacteria were lysed, using bead beating (14). For digestion
of proteins, to generate peptides, sodium deoxycholate (SDC, 5% in
20 mM ammonium bicarbonate, pH 8) was added to 1% (w/v) final
concentration. Trypsin (2 g/ml, 100 l ammonium bicarbonate, 20
mM pH 8) was added and samples were digested for 8 h at 37 °C.
SDC was removed by precipitation by addition of formic acid (FA)
followed by centrifugation at 13,000  g for 10 min. Supernatants
containing the peptides were stored at 20 °C until analysis. The
peptide samples were not reduced or alkylated prior to MS analysis
(supplemental Fig. S3).
NanoLC-MS/MS Analysis—Peptide samples were desalted, using
PepClean C18 spin columns (Thermo Fisher Scientific, MA), accord-
ing to the manufacturer’s guidelines. MS analyses were carried out,
using Q Exactive or a QExactive HF MS (Thermo Fisher Scientific)
interfaced with an Easy nLC 1200 liquid chromatography system
(Thermo Fisher Scientific). Peptides were trapped on an Acclaim
Pepmap 100 C18 trap column (100 m  2 cm, particle size 5 m,
Thermo Fischer Scientific) and separated on an in-house packed
analytical column (75 m  300 mm, particle size 3 m, Reprosil-Pur
C18, Dr. Maisch, Germany), using a gradient from 7% to 35% B over
35, 50, or 75 min followed by an increase to 100% B for 5 min at a flow
of 300 nL/min. Solvent A was 0.2% formic acid and solvent B was
80% acetonitrile in 0.2% formic acid. The instrument operated in
data-dependent mode where the precursor ion mass spectra were
acquired at a resolution of 70,000 (QE) or 60,000 (QEHF), the 10 most
intense multiply charged ions were isolated in a 2.0 Da isolation
window and fragmented using collision energy HCD settings at 27.
MS2 spectra were recorded at a resolution of 35,000 (QE) or 30,000
(QEHF). Dynamic exclusion was set to 20–30 s with 10 ppm toler-
ance. Inclusion lists, containing the candidate peptide biomarkers for
each species, were used in the qualification and verification phases
together with pick others to improve the sensitivity of the MS-method.
Them/z ratios (a maximum of 50 for each MS-analysis) corresponding
to specific peptide biomarkers were prioritized for fragmentation even
if they were not among the Top10 most abundant peptides.
TCUP Bioinformatics Pipeline—Raw data were evaluated using the
TCUP bioinformatics pipeline (27) to identify species-unique
peptides. The LC-MS/MS output was converted from the proprietary
Thermo Xcalibur RAW format to the open-source mzXML format (33),
using ReAdW (34) (version 201411.xcalibur), with command-line ar-
guments: “–nocompress -gzip.” The X! Tandem spectrum search
engine (version VENGEANCE Dec. 15, 2015) (35, 36) was used to
identify peptides from the mass spectra with the following settings:
fragment monoisotopic mass error  20; parent monoisotopic mass
error plus  5; parent monoisotopic mass error minus  5; fragment
mass type monoisotopic, dynamic range  100.0; total peaks  50;
maximum parent charge  4; minimum parent mh  800.0; mini-
mum fragment m/z  100.0, minimum peaks  15, potential modifi-
cation mass  16.0@M, maximum valid expectation value  1.0. In
addition, X! Tandem peptides were also filtered to only allow peptides
with a hyperscore of 30 in downstream analyses (37). Values for all
X!Tandem settings are available in supplemental file 1. The reference
database used in this step was a customized database consisting of
56,967,781 non-redundant proteins from the NCBI GenBankTM NR
(38) and 6,320,906 peptide sequences from the reference genomes
archived within the Human Microbiome Project (39). All sequences
containing unidentified peptides (“X”), as well as duplicates of se-
quences shared between the two databases, were removed. The
resulting database used with X! Tandem contained a total of
59,349,300 distinct protein sequences. The taxonomic hierarchy used
in TCUP was based on the complete NCBI Taxonomy (40) (taxdump
downloaded Nov. 17, 2015) and each reference genome in the refer-
ence database was associated with a unique node in the taxonomic
tree. The search parameters were set, according to Boulund et al.
(27). All peptides presented in Tables I–IV were mapped against
RefSeq sequences (Oct 2018) using BLAST (https://blast.ncbi.
nlm.nih.gov/Blast.cgi).
Generation of Targeted Database and MS-inclusion Lists—A tar-
geted database was compiled, including 15,417 species-unique pep-
tides identified by TCUP in at least one of the MS analyses of the
representative strains of the four bacterial species (Table V, supple-
mental Table S2). The smaller targeted database was used for in-
creasing the probability of positive identification of the relevant pep-
tide biomarkers. Additionally, MS-inclusion lists used in the later
qualifications phase were generated. Peptides that were detected in
all strains and all MS analyses were ranked the highest in the lists
(supplemental Fig. S1). The lists contain the 100 highest-ranked pep-
tides for each species.
These peptide lists were revised after the qualification phase and
the peptides detected in the samples with a lower number of spiked
pathogenic bacteria were ranked the highest. In verification phase,
the clinical samples were analyzed in batches and the peptide lists
were again revised after each batch, according to the following cri-
teria: (1) Identified peptides from the list were verified as a peptide
biomarker candidate by its presence in clinical samples; (2) Peptides
identified in the clinical samples by TCUP, but not present in the
inclusion lists, were added to updated versions of the inclusion lists;
(3) Peptide biomarker candidates present in the initial inclusion lists,
but not detected in the clinical samples, were removed from updated
inclusion lists or were given a lower ranking (supplemental Data
S1–S4). After ranking, the final lists of peptides for each of the
Species-unique Peptide Biomarkers of Bacterial Pathogens
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bacterial species were reduced to the top 16–18 peptide biomarker
candidates (supplemental Fig. S3, Tables I–IV).
Database Matching—In parallel with the TCUP bioinformatics pipe-
line, the data was matched, using Proteome Discoverer (Thermo
Fisher Scientific, version 1.4), against the targeted database. Mascot
2.5 (Matrix Science, MA) was used as a search engine with precursor
mass tolerance of 5 ppm and fragment mass tolerance of 200 mmu
and variable methionine oxidation. Fixed Value with a maximum delta
Cn of 0.05 was employed in the database matching and the peptides
used for protein identification were filtered at 1% FDR. The fragmen-
tation spectra and ion series for all detected peptides in the clinical
samples were inspected manually to verify correct identifications.
Targeted MS (PRM) Analyses—For each of the four bacterial spe-
cies, the top 16–18 peptide biomarker candidates (Tables I–IV, sup-
plemental Data S5–S8), most prominently found in clinical samples
were analyzed, using parallel reaction monitoring (PRM) on a Q Ex-
active HF (Thermo Fisher Scientific). Separation was performed, using
a 50 min gradient, as stated above and the precursor ions of the
peptides were targeted without scheduling. The QEHF orbitrap res-
olution was 30 000, a quadrupole isolation window of 1.2 Da and
collision energy HCD settings at 27 were used. PRM data were
analyzed using Skyline (version 4.2.0) (39). Peak picking was manually
checked and corrected in accordance with the retention time, transi-
tions and mass accuracy to confirm the identities of peptides. For this
proof-of-concept, the PRM method used here was employed to bias
toward detection of the peptide biomarkers of interest (Tier 3, as
defined in the MCP guidelines).
The MS proteomics data (MS/MS-spectra for all species-unique
peptides presented in Tables I–IV, as well as raw-files and PD1.4
search files of representative clinical samples) have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository
with the data set identifiers PXD014522.
Experimental Design and Statistical Rationale—The workflow of
how to discover, qualify and verify the species-unique peptides is
shown in Fig. 1 and supplemental Fig. S4. The number of bacterial
strains included in the discovery phase of finding species-unique
peptides were S. aureus (12 strains), M. catarrhalis (11 strains), H.
influenzae (9 strains) and S. pneumoniae (7 strains), all analyzed in
triplicate, resulting in, at least, 21 MS analyses per species (Table V).
The number of identified species-unique peptides increased with the
number of analyzed strains. However, at a certain stage, analyses of
additional strains did not contribute to further increase in the number
of species-unique peptides and the number of strains selected per
species was concluded to be satisfactory (supplemental Figs. S5–S8).
In the verification phase, to verify the presence of the species-
unique peptides in patient samples, without prior culturing, the num-
ber of clinical samples included was 218. As this study was focused
on the discovery of species-unique peptides no replicate analyses
were performed at this stage, as it was deemed more important to
analyze many individual clinical samples.
RESULTS
In summary, the workflow of discovering, qualifying and
verifying the species-unique peptides as promising peptide
biomarker candidates was divided into four phases (Fig. 1 and
supplemental Fig. S4). First, in the discovery phase, species-
unique peptides were identified from pure bacterial cultures.
Subsequently, in the qualification phase, negative clinical
samples were spiked with bacterial cells in order to ensure
that the peptides could be detected in the context of a real-
istic clinical sample. In the verification phase, positive clinical
samples were analyzed to verify the species-unique peptides
most frequently found in clinical samples. Last, as a proof-of-
concept, positive clinical samples were analyzed using a tar-
geted MS approach with the selected candidate peptide bio-
markers as targets.
In the discovery phase, several representative strains from
each of the four target species, S. aureus (13 strains), M.
FIG. 1. Illustration showing the process employed for identifying species-unique peptides as potential peptide biomarker candi-
dates. During the process, bacterial cultures, representing genomic and proteomic variation within the species, as well as clinical samples,
were analyzed. The purpose of this workflow was to initially identify as many species-unique peptides as possible and in later phases narrow
down the number of peptides to the most promising peptide biomarker candidates to be used for diagnostic analyses.
Species-unique Peptide Biomarkers of Bacterial Pathogens
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catarrhalis (11 strains), H. influenzae (9 strains) and S. pneu-
moniae (7 strains) were selected to reflect the genetic varia-
tion within the species (supplemental Table S1). Each species
was analyzed with a minimum of 21 MS runs resulting in
identified species-unique peptides (Table V). The largest num-
ber of species-unique peptides were found in S. aureus and
M. catarrhalis (5847 and 5810, respectively), H. influenzae
strains comprised 2978 species-unique peptides, whereas
the fewest number of species-unique peptides (782) was de-
tected in strains of S. pneumoniae. The peptides were ranked,
based on the number of strains in which they were detected.
These results from the MS-analyses were compiled to a da-
tabase containing the 15,417 species-unique peptides (sup-
plemental Table S2). The most promising peptide biomarker
candidates, based on the number of strains they were found
in, were reduced to lists of 100 peptides for each species
(supplemental Fig. 1).
In the qualification phase, the suitability of the species-
unique peptides as potential peptide biomarker candidates
was evaluated. Negative clinical samples were spiked with
varying concentrations of bacterial cells (supplemental Fig.
S2) and the MS analyses were performed using inclusion lists
with the hundred highest ranking species-unique peptides
identified in the discovery phase. The number of bacterial
cells per ml of sample ranged from 100 to 1 million cells/ml,
reflecting the variation in the number of bacteria cells typical
for nasopharyngeal/nasal swab samples; bacterial loads vary
during different phases of infection and are also dependent on
the pathogen (41, 42). The selected range was considered to
realistically reflect both weakly- and strongly-infected sam-
ples. The species-unique peptides detected in samples con-
taining the lowest number of bacterial cells, ranging from 1000
to 10,000, were deemed to be promising peptide biomarker
candidates (supplemental Table S3). The ranking of the pep-
tides in the respective inclusion lists were revised in accord-
ance with the results from the qualification phase (supplemen-
tal Fig. S2).
In the verification phase, 218 clinical respiratory tract sam-
ples (312 MS injections) were included, from which isolations
of S. aureus, M. catarrhalis, H. influenzae and/or S. pneu-
moniae, were reported. These samples were thus used as
“positive control” samples for MS analyses. The clinical sam-
ples were reported by the Clinical Microbiology Laboratory to
contain at least one of the pathogens included in the study,
but in many cases, samples displaying co-infection with two
or more of these four pathogens, were included. By analyzing
these samples, peptide biomarker candidates were detected
and identified, confirming that the proteins from which the
peptide biomarker candidates originate, are present in vivo.
The peptides most prominently detected in clinical samples,
and their corresponding proteins, as well as the number of
times they were detected in the cultures of bacterial reference
strains, are presented in Tables I, II, III, and IV. In order to
verify the identities of the peptides in the clinical samples, all
fragmentation spectra were inspected manually. The frag-
mentation spectra and ion series for a top ranked peptide for
each of the four species are shown in supplemental Figs.
S9–S12. During the analysis of the clinical samples in the
verification phase, the lists containing the peptide bio-
marker candidates were continuously revised according to
the ranking of the peptide. The final lists were reduced to
contain only the 15–20 most promising peptide biomarker
TABLE I
The peptide biomarker candidates of S. aureus and the proteins from which they originate
Peptide sequence
Number of times
detected in 36
MS analyses of
S. aureus
cultures
Number of times
detected in
unique clinical
samples
Protein (GenBank accession number and
description)
TVQPIDVDTIVASVEK 36 22 AKJ16950.1 2-oxoisovalerate dehydrogenase
QAGVGAAVVAELSER 36 18
ELINNIQSGQR 36 15 AKJ17520.1 Preprotein translocase subunit YajC
LGISDGDVEETEDAPK 36 16 AKJ17148.1 Recombinase RecA
ALLNNMVQGVSQGYVK 36 14 AKJ18065.1 50S ribosomal protein L6
SNVNDATDYSSETPEGK 36 12 AKJ17216.1 Transketolase
ANNVATDANHSYTSR 36 13 AKJ17623.1 Hypothetical protein
ILAESPNLAISSSSR 35 10 AKJ16422.1 HAD family hydrolase
NVVEIPLNDEEQSK 31 9 AKJ16109.1 Lactate dehydrogenase
ATEATNATNNQSTQVSQATSQPINFQVQK 24 7 AKJ16987.1 Heme transporter IsdA
IHLVGDEIANGQGIGR 35 8 AKJ17576.1 Pyruvate kinase
NISNNVLVTIDAAQGK 13 6
TAKPVAEVESQTEVTE 26 10 AKJ16406.1 DNA-directed RNA polymerase
subunit beta’
SQGVSEEELNESIDR 29 1 AKJ16022.1 Acetaldehyde dehydrogenase
AEENGLTVVDAFNFEAPK 16 7 AKJ18079.1 50S ribosomal protein L4
LLGINATIVMPETAPQAK 1 1 AKJ17317.1 Threonine dehydratase
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candidates for the proof-of-concept targeted MS analyses
(supplemental Fig. 3, supplemental Data S1–S4).
Finally, as a proof-of-concept, a PRM method was devel-
oped, offering increased sensitivity and high selectivity (22),
by targeting the most suitable peptide biomarker candidates
identified in the verification phase (Tables I–IV, supplemental
Data S5–S8, supplemental Table S4, Fig. 2). The peptide
identities were verified by aligning the retention time together
with correct transitions and mass accuracy.
DISCUSSION
The selection of species-unique peptides was performed
throughout the phases of discovery, qualification and verifi-
cation (Fig. 1, supplemental Fig. S4). The purpose of these
phases was to narrow down the number of species-unique
peptides for determining the most suitable peptide biomarker
candidates, from the starting point of analyses of bacterial
reference cultures in the discovery phase, representing the
genomic and proteomic variation of the species included in
the study. In the qualification phase, the species-unique pep-
tides detected in the lowest number of spiked cells displayed
suitable properties for ionization, fragmentation and detection
in the MS-analyses. Also, they were not suppressed by con-
taminating peptides of human origin from the clinical samples.
Furthermore, the results show that sufficient amounts of bac-
terial cells were recovered during the removal of the human
biomass, also suggesting that the limited amount of bacterial
pathogen material in clinical respiratory tract samples can be
recovered for detection in the MS-analysis.
The results from the subsequent verification phase demon-
strate the importance of confirming data stemming from cul-
tures of bacterial reference strains, by analyses of clinical
samples. As expected, not all the species-unique peptides
identified in the bacterial cultures were detected in the clinical
samples. During traditional protocols including cultivation, the
conditions are selected to best promote growth for recovery
of enough biomass for downstream analyses. However, dur-
ing invasion of the host, pathogens are known to experience
stress, such as nutrient limitation, low pH, etc. Exposure to
host environments also triggers virulence responses by
pathogens and, thus, virulence factors may be expressed and
present in high levels in clinical samples, whereas they may be
present at limited levels in culture. Therefore, pathogens dis-
play different protein profiles in vivo, compared with what is
observed in defined cultivation conditions (43, 44).
TABLE II
The peptide biomarker candidates of M. catarrhalis and the proteins from which they originate
Peptide sequence
Number of times
detected in
number of 33
MS analyses of
M. catarrhalis
cultures
Number of times detected
in unique clinical samples
Protein (GenBank accession number and
description)
VVLAGDTVVSDR 33 14 WP_003666427.1 TonB-dependent receptor
QIVSNAGDEASVIVNEVK* 33 18 WP_063454121.1 Chaperonin GroEL
AIAQVGSISANSDATIGELISK 29 16
ELSNTAAETQPK 33 18 WP_003659702.1 30S ribosomal protein S1
VDATVDAQNPTK 24 16 WP_003660336.1 Hypothetical protein
QSDVGQLTGK 5 9
FNATAALGGYGSK 31 12 WP_063454085.1 Cell surface protein
THTSALAEENQQASIPR 33 12 WP_063454087.1 Cell division protein FtsZ
YVVEGANMPLDAQAIDIVR 17 11 WP_049156084.1 NADP-specific glutamate
dehydrogenase
SQIYQTTASVSGAR 33 9 WP_003657351.1 Ohr family peroxiredoxin
LLNETTGQVVPK 33 8 WP_003657987.1 DUF4377 domain-
containing protein
SSENVVVVSVR 33 10 WP_063454071.1 Electron transfer
flavoprotein subunit beta
AISYGNSADAQPYVGAK 33 10 WP_003658939.1 Porin family protein
GLPVSNSGAPISVPVGQATLGR 31 8 WP_003658974.1 F0F1 ATP synthase
subunit beta
VNYNGDTDTVTLSGVAK 33 13 WP_003656943.1 Peptidoglycan-binding
protein LysM
AVATQQATVSAEYLQK 5 10 WP_003657125.1 ABC transporter
substrate-binding protein
ADSGLSESEIEEMIR 32 12 WP_003669031.1 Molecular chaperone
DnaK
LGAQEAELVSNSK 33 7 WP_003660298.1 CTP synthase
*This peptide was also found in samples spiked with the fewest number of cells (supplemental Table S2).
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TABLE III
The peptide biomarker candidates of H. influenzae and the proteins from which they originate
Peptide sequence
Number of times
detected 26 MS
analyses of H.
influenzae
cultures
Number of times
detected in
unique clinical
samples
Protein (GenBank accession number and
description)
GVAADAISATGYGK* 22 22 WP_038441355.1 Porin OmpA
ANLKPQAQATLDSIYGEMSQVK 5 6
ADSVANYFVAK  5
GSYEVLDGLDVYGK 12 3
LSQERADSVANYFVAK**  2
AVVYNNEGTNVELGGR* 22 14 WP_058222193.1 Porin
YDANNIIAGIAYGR* 13 6
ATHNFGDGFYAQGYLETR 15 5
AVVYNNEGTKVELGGR  5
QQVNGALSTLGYR 18 1
YVPTNGNTVGYTFK  4
LSVIAEQSNSTR* 4 1
SADLTNEVAVGDVVEAK 4 6 WP_011272719.1 30S ribosomal protein S1
SADLTSEVAVGDVVEAK 11 2
TSPTQNLSLDAFVAR 9 5 WP_058222202.1
WP_050846043.1
ShlB/FhaC/HecB family
hemolysin
secretion/activation
protein
AQYIVEQVIGQAR 26/29 2 WP_011272712.1 Pyruvate dehydrogenase
(acetyl-transferring),
homodimeric type
*This peptide was also found in samples spiked with the fewest number of cells (supplemental Table S2).
**Peptide with missed cleavage includes ADSVANYFVAK.
TABLE IV
The peptide biomarker candidates of S. pneumoniae and the proteins from which they originate
Peptide sequence
Number of times
detected in 21
MS analyses of
S. pneumoniae
cultures
Number of times
detected in
unique clinical
samples
Protein
(GenBank accession number
and description)
VSDVAESTGEFTSEQFEK* 21 22 WP_000064115.1 Asp23/Gls24 family envelope stress response
proteinGAANGVVSHENTR*  9
EEAPVASQSK  9 WP_001035310.1 Hypothetical protein
SADQQAEEDYAR  8
APLQSELDTK  3
LKEIDESDSEDYVK  3
NVEIIEDDKQGVIR 1 10 WP_000245505.1 30S ribosomal protein S8
NLPVGSDGTFTPEDYVGR 20 8 WP_001291372.1 Methionine–tRNA ligase
TLELEIAESDVK  5 WP_000458177.1 Hypothetical protein
DIGLANDGSIVGINYAK 12 5 WP_000927809.1 Sugar ABC transporter substrate-binding
protein
IAELEYEVQR  6 WP_001008677.1 Asp-tRNA(Asn)/Glu-tRNA(Gln) amidotransferase
subunit GatB
AVAAADAADAGAAK 3 3 WP_001196960.1 50S ribosomal protein L7/L12
GQDWVIAAEVVTKPEVK 16 5 WP_000116461.1 Trigger factor
TLSPEEYAVTQENQTER  6 WP_000998307.1 Peptide-methionine (R)-S-oxide reductase
KDEAEAAFATIR  3 WP_001284361.1 Thiol-activated toxin pneumolysin
SQPSSETELSGNKQEQER 16 2 WP_078148305.1 Sialidase
IGVISVVEDGDEALAK  2 WP_000808063.1 Elongation factor Ts
VAYFNEIDTYSEVK  2 WP_000685088.1 Nucleotide sugar dehydrogenase
*This peptide was also found in samples spiked with the fewest number of cells (supplemental Table S2).
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Differences in protein profiles for cultured bacteria and
clinical samples can be seen clearly in the analyses of S.
pneumoniae and H. influenzae (Table III and IV). For these two
species, 4 of the most promising species-unique peptides of
H. influenzae, and 13 for S. pneumoniae, identified in the
clinical samples, were not found in the analyses of any of the
cultured bacterial reference strains. For M. catarrhalis and S.
aureus, many of the peptide biomarker candidates originated
from highly abundant cytosolic proteins, including ribosomal
proteins. Because cytosolic house-keeping proteins, in gen-
eral, are present in relatively high levels, regardless of growth
conditions, the most prominent peptide biomarker candidates
would most likely originate from the house-keeping proteins
when analyzing clinical samples. These results are consistent
with traditional gene-based approaches and MALDI-TOF
MS, which both commonly use house-keeping genes and
proteins as targets for identification. In contrast, many of the
proteins identified from the peptide biomarker candidates for
S. pneumoniae and H. influenzae include those associated
with the surface of the cells. This might be because of the
differences in taxonomic structure of the different species. M.
catarrhalis and S. aureus are phylogenetically more distant
from their closest related species and as a result their house-
keeping proteins, including ribosomal proteins, do not display
substantial sequence homology of the species closest to
them. However, for S. pneumoniae and H. influenzae, the
taxonomic structures around these species are more complex
and the house-keeping proteins, including ribosomal proteins,
display a higher degree of sequence homology to closely
related species. Therefore, it may be more difficult to find
peptide biomarker candidates originating from their house-
keeping proteins. Surface-associated proteins have different
functions, helping the bacteria survive in diverse and dynamic
ecological niches and, particularly, these proteins are often
involved in host-pathogen interactions, effectively function-
ing, as virulence factors (18). Many of the proteins identified
from S. pneumoniae and H. influenzae by their respective
peptide biomarker candidates belong to the group of surface-
associated virulence factors. This can be explained by the fact
that these proteins are the ones differentiating them from their
closest relatives, as well as being expressed significantly in
clinical samples.
In conclusion, the aim of this study was to initially identify
species-unique peptides in cultures of bacterial reference
strains from respiratory tract infectious bacteria (S. aureus,M.
catarrhalis, H. influenzae and S. pneumoniae) and subse-
quently determine the most promising and applicable peptide
biomarker candidates in clinical samples. Previous proteomic
studies, focused on discovery of peptide biomarker candi-
dates for infectious disease diagnostics, have mostly been
performed using in vitro model system samples, mainly be-
cause of analytical challenges such as recovery of sufficient
amount of bacterial proteins from human clinical samples and
the high background of human contaminating proteins ob-
structing the detection of peptide biomarkers from bacteria. In
this study, a simple workflow was developed, including re-
moval of human material from clinical respiratory tract sam-
ples, whereas still being able to recover sufficient amounts
of bacteria for detection of peptide biomarker candidates.
Importantly, several hundreds of clinical respiratory tract
samples were analyzed directly, without any culturing, thus
confirming the presence of peptide biomarker candidates in
the clinical samples and, at the same time, their relevance
for identifications of the pathogens and as diagnostic
biomarkers.
In further studies, the peptide biomarker candidates, will be
employed in the development of a targeted MS-approach, as
demonstrated here (Fig. 2). Targeted approaches, such as
PRM and SRM/MRM (Selected Reaction Monitoring/Multiple
reaction monitoring) have several advantages, compared with
discovery phase studies, such as higher sensitivity and spec-
ificity, simplified MS-analysis and data evaluation (22). In this
study, MS proteomics analyses of clinical samples that were
confirmed to be positive for a respiratory tract pathogen,
determined by standard clinical microbiology methodologies,
was employed as a cost-effective approach for identifying
peptides from the relevant pathogens included in this study.
Notably, samples were frozen until correct identifications
could be confirmed by standard means, although, that freez-
ing step may have had a negative effect on some species,
sensitive to freezing, thus reducing the number of intact cells
prior to the sample preparation for the MS analysis workflow.
For comparison of the peptide biomarker approach versus
traditional culture-based methods for clinical microbiology
diagnostics, the experimental design would be different, i.e.
samples would not be frozen prior to processing and more of
the sample volume would be dedicated and processed for
proteotyping. Furthermore, targeted MS approaches, such as
TABLE V
Number of strains analyzed, corresponding number of MS analyses and the resulting number of species-unique peptides found for each of the
species
Species Number of strains Number of MS analyses Number of species-unique peptides
S. aureus 12 36 5,847
M. catarrhalis 11 33 5,810
H. influenzae 9 26 2,978
S. pneumoniae 7 21 782
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parallel reaction monitoring (PRM) would be employed, as
demonstrated here by the proof-of-concept experiment,
shown in Fig. 2, wherein a small sub-set of positive clinical
samples were analyzed, targeting only the peptide biomarker
candidates presented in Tables I–IV. In the continued devel-
opment of the targeted approach, a larger ensemble of pep-
tide biomarkers (selected from the species-unique peptides in
supplemental Table S2) could be employed. Further studies
FIG. 2. Direct analyses of clinical respiratory tract samples, using PRM, targeting the most promising peptide biomarker candidates,
presented in Tables I–IV. The peptide intensities are summed up fragment ion intensities of the peptides most abundant charge state.
Whenever peptides contain a methionine the more abundant oxidized form is shown in the spectra. The peptide peaks are labeled with
numbers corresponding to their sequences.
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are necessary to compare the use of MS-based peptide bio-
markers for identifying respiratory tract pathogens to tradi-
tional methodologies - including cultivation-dependent tech-
niques such as MALDI-TOF MS - in terms of sensitivity,
specificity, speed, and cost. However, as demonstrated here
with the proof-of concept PRM analysis, we show the value of
a targeted approach for future high throughput and specific
detection of bacteria within complex samples, such as clinical
respiratory tract samples, i.e. without prior cultivation steps.
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